Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018224053) POLYPEPTIDE EYE ABSORPTION ENHANCER AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/224053 International Application No.: PCT/CN2018/095539
Publication Date: 13.12.2018 International Filing Date: 13.07.2018
IPC:
C07K 7/08 (2006.01) ,A61K 38/10 (2006.01) ,A61K 47/64 (2017.01) ,A61P 27/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
08
having 12 to 20 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10
Peptides having 12 to 20 amino acids
[IPC code unknown for A61K 47/64]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
Applicants:
复旦大学 FUDAN UNIVERSITY [CN/CN]; 中国上海市 浦东新区张衡路826号复旦大学药学院 School of Pharmacy, No.826, Zhangheng Road, Pudong District Shanghai 201203, CN
Inventors:
魏刚 WEI, Gang; CN
江宽 JIANG, Kuan; CN
陆伟跃 LU, Weiyue; CN
刘畅 LIU, Chang; CN
太玲钰 TAI, Lingyu; CN
高欣 GAO, Xin; CN
Agent:
北京天昊联合知识产权代理有限公司 TEE & HOWE INTELLECTUAL PROPERTY ATTORNEYS; 中国北京市 东城区建国门内大街28号民生金融中心D座10层麦善勇 Toby MAK 10th Floor, Tower D, Minsheng Financial Center, 28 Jianguomennei Avenue, Dongcheng District Beijing 100005, CN
Priority Data:
201710414334.705.06.2017CN
Title (EN) POLYPEPTIDE EYE ABSORPTION ENHANCER AND USE THEREOF
(FR) STIMULATEUR D'ABSORPTION OCULAIRE POLYPEPTIDIQUE ET UTILISATION ASSOCIÉE
(ZH) 多肽类眼部吸收促进剂及其应用
Abstract:
(EN) The present invention belongs to the field of pharmaceutical preparations and relates to designing a series of lipophilic derivatives by using the wild-type membrane-penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the eye tissue, are not toxic to the eye tissue, and can achieve intraocular drug delivery by means of a non-invasive route as eye absorption enhancers, increasing the bioavailability of a drug in the eyes. These penetratin derivatives and an ocular drug delivery system constructed with same are used for ophthalmic instillation, can replace intraocular injection administration, the compliance thereof to patients being poor, and enhance the convenience and safety of treating intraocular diseases and diseases of the fundus.
(FR) La présente invention se rapporte au domaine des préparations pharmaceutiques et concerne la conception d'une série de dérivés lipophiles à l'aide de la pénétratine peptidique de pénétration membranaire de type sauvage. Les dérivés de pénétratine de la présente invention ont une forte capacité à pénétrer dans le tissu oculaire, ne sont pas toxiques pour ce dernier, et peuvent atteindre une administration de médicament intraoculaire au moyen d'une voie non invasive en tant que stimulateurs d'absorption oculaire, augmentant la biodisponibilité d'un médicament dans les yeux. Les dérivés de pénétratine de la présente invention et un système d'administration de médicament oculaire produit avec ceux-ci sont utilisés, pour l'instillation ophtalmique, peuvent remplacer l'administration par injection intraoculaire, leur conformité à des patients étant faible, et la commodité et la sécurité de traitement de maladies intraoculaires et de maladies du fond d'œil étant améliorées.
(ZH) 属药物制剂领域,涉及利用野生型穿膜肽penetratin设计一系列亲脂性衍生物。这些penetratin衍生物具有很强的穿透眼组织能力,而且不会产生眼部组织毒性,作为眼部吸收促进剂可通过无创途径实现眼内药物递送,增加药物的眼部生物利用度。这些penetratin衍生物及其构建的眼部给药系统用于滴眼给药,可替代患者顺应性差的眼内注射给药,增强了眼内和眼底疾病治疗的便利性和安全性。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)